Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Gallo
University of California, San Diego, Department: Dermatology
Should you be removed from our database? Contact us at [email protected]. Read more below.
MatriSys Bioscience, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Gallo is a co-founder of MatriSys Bioscience, Inc. (MatriSys) and serves as the Chair of the company's Scientific Advisory Board. He holds (b)(4) equity in the company and receives compensation for his consulting activities. The company is developing rational microbiome therapies based on Dr. Gallo's basic and clinical research for the top five dermatology and skin care conditions, Acne, Atopic Dermatitis, Rosacea, Psoriasis and Skin Infections. The company's "Good Bug", S. hominis, is highly potent against the "Bad Bug", Staph aureus. The project aims to increase understanding of adipogenesis as a skin host defense mechanism and help develop immunotherapies for improving the global burden of Staph aureus skin infection.
Skin Defense by Dermal Adipocytes
Staphylococcus aureus is responsible for the majority of skin and soft tissue infections in humans and obesity has been identified as a factor that increases the risk of skin infections. We recently discovered that dermal adipocytes defend against invasive S. aureus infections, thus permitting us to propose that adipose tissue imbalance upon obesity may impair the beneficial immune response provided during adipogenesis. This proposal will increase our understanding of adipogenesis as a skin host defense mechanism and help to develop immunotherapies for improving the global burden of S. aureus skin infection.
Filed on October 17, 2016.
Tell us what you know about Richard Gallo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Gallo filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Gallo | University of California, San Diego | Conflict of Interest | Sente | $100,000 - $149,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | Sente | $20,000 - $39,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $10,000 - $19,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $10,000 - $19,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $10,000 - $19,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $10,000 - $19,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $0 - $4,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $0 - $4,999 |
| Richard Gallo | University of California, San Diego | Conflict of Interest | MatriSys Bioscience, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.